[1] Montgomery MK, Turner N. Mitochondrial dysfunction and insulin resistance: An update. Endocr Connect 2015;4:R1–15. doi:10.1530/EC-14-0092.
[2] Rovira-Llopis S, Bañuls C, Diaz-Morales N, Hernandez-Mijares A, Rocha M, Victor VM. Mitochondrial dynamics in type 2 diabetes: Pathophysiological implications. Redox Biol 2017;11:637–45. doi:10.1016/j.redox.2017.01.013.
[3] Antoun G, McMurray F, Thrush AB, Patten DA, Peixoto AC, Slack RS, et al. Impaired mitochondrial oxidative phosphorylation and supercomplex assembly in rectus abdominis muscle of diabetic obese individuals. Diabetologia 2015;58:2861–6. doi:10.1007/s00125-015-3772-8.
[4] Sivitz WI, Yorek MA. Mitochondrial dysfunction in diabetes: From molecular mechanisms to functional significance and therapeutic opportunities. Antioxidants Redox Signal 2010;12:537–77. doi:10.1089/ars.2009.2531.
[5] Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, et al. Mitochondrial dysfunction in the elderly: Possible role in insulin resistance. Science (80- ) 2003;300:1140–2. doi:10.1126/science.1082889.
[6] Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired Mitochondrial Activity in the Insulin-Resistant Offspring of Patients with Type 2 Diabetes. N Engl J Med 2004;350:664–71. doi:10.1056/nejmoa031314.
[7] Kelley DE, He J, Menshikova E V, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002;51:2944–50. doi:10.2337/diabetes.51.10.2944.
[8] Maechler P, Wollheim CB. Mitochondrial function in normal and diabetic β-cells. Nature 2001;414:807–12. doi:10.1038/414807a.
[9] Gore E, Duparc T, Genoux A, Perret B, Najib S, Martinez LO. The Multifaceted ATPase Inhibitory Factor 1 (IF1) in Energy Metabolism Reprogramming and Mitochondrial Dysfunction: A New Player in Age-Associated Disorders? Antioxid Redox Signal 2022. doi:10.1089/ars.2021.0137.
[10] Genoux A, Pons V, Radojkovic C, Roux-Dalvai F, Combes G, Rolland C, et al. Mitochondrial Inhibitory Factor 1 (IF1) Is Present in Human Serum and Is Positively Correlated with HDL-Cholesterol. PLoS One 2011;6:e23949. doi:10.1371/journal.pone.0023949 PONE-D-11-04795 [pii].
[11] Genoux A, Ruidavets J-B, Ferrières J, Combes G, Lichtenstein L, Pons V, et al. Serum IF1 concentration is independently associated to HDL levels and to coronary heart disease: the GENES study. J Lipid Res 2013;54:2550–8. doi:10.1194/jlr.P036335.
[12] Genoux A, Lichtenstein L, Ferrières J, Duparc T, Bongard V, Vervueren P-L, et al. Serum levels of mitochondrial inhibitory factor 1 are independently associated with long-term prognosis in coronary artery disease: the GENES Study. BMC Med 2016;14:125. doi:10.1186/s12916-016-0672-9.
[13] Wargny M, Smati S, Pichelin M, Bigot-Corbel E, Authier C, Dierry V, et al. Fatty liver index is a strong predictor of changes in glycemic status in people with prediabetes: The IT-DIAB study. PLoS One 2019;14:e0221524. doi:10.1371/journal.pone.0221524.
[14] Ramin-Mangata S, Wargny M, Pichelin M, Le May C, Thédrez A, Blanchard V, et al. Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes. Atherosclerosis 2020;293:49–56. doi:10.1016/j.atherosclerosis.2019.11.027.
[15] Croyal M, Wargny M, Chemello K, Chevalier C, Blanchard V, Bigot-Corbel E, et al. Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes. Cardiovasc Diabetol 2022;21:21. doi:10.1186/s12933-022-01452-5.
[16] Vion J, Sramkova V, Montastier E, Marquès MA, Caspar-Bauguil S, Duparc T, et al. Metabolic and cardiovascular adaptations to an 8-wk lifestyle weight loss intervention in younger and older obese men. Am J Physiol - Endocrinol Metab 2021;321:E325–37. doi:10.1152/ajpendo.00109.2021.
[17] Vellas B, Carrie I, Gillette-Guyonnet S, Touchon J, Dantoine T, Dartigues JF, et al. MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER’S DISEASE: DESIGN AND BASELINE DATA. J Prev Alzheimer’s Dis 2014;1:13–22. doi:10.14283/jpad.2014.34.
[18] Raffin J, Angioni D, Giudici K V, Valet P, Aggarwal G, Nguyen AD, et al. Physical Activity, Body Mass Index, and Blood Progranulin in Older Adults: Cross-Sectional Associations in the MAPT Study. Journals Gerontol Ser A 2022. doi:10.1093/gerona/glac018.
[19] Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol 2017;16:377–89. doi:10.1016/S1474-4422(17)30040-6.
[20] Genoux A, Duparc T, Ruidavets JB, Ingueneau C, Najib S, Ferrières J, et al. A reference measurement of circulating ATPase inhibitory factor 1 (IF1) in humans by LC-MS/MS: Comparison with conventional ELISA. Talanta 2020;219:121300. doi:10.1016/j.talanta.2020.121300.
[21] Blanchard V, Garçon D, Jaunet C, Chemello K, Billon-Crossouard SS, Aguesse A, et al. A high-throughput mass spectrometry–based assay for large-scale profiling of circulating human apolipoproteins. J Lipid Res 2020;61:jlr.D120000835. doi:10.1194/JLR.D120000835.
[22] Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–9. doi:10.1007/BF00280883.
[23] RCoreTeam. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna (2016). 2016:2013.
[24] Cabou C, Honorato P, Briceño L, Ghezali L, Duparc T, León M, et al. Pharmacological inhibition of the F1-ATPase/P2Y1 pathway suppresses the effect of apolipoprotein A1 on endothelial nitric oxide synthesis and vasorelaxation. Acta Physiol 2019;226:e13268. doi:10.1111/apha.13268.
[25] Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezon E, Champagne E, et al. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003;421:75–9.
[26] Castaing-Berthou A, Malet N, Radojkovic C, Cabou C, Gayral S, Martinez LO, et al. PI3Kβ Plays a Key Role in Apolipoprotein A-I-Induced Endothelial Cell Proliferation Through Activation of the Ecto-F1-ATPase/P2Y1 Receptors. Cell Physiol Biochem 2017;42:579–93. doi:10.1159/000477607.
[27] Cardouat G, Duparc T, Fried S, Perret B, Najib S, Martinez LO. Ectopic adenine nucleotide translocase activity controls extracellular ADP levels and regulates the F1-ATPase-mediated HDL endocytosis pathway on hepatocytes. Biochim Biophys Acta 2017;1862:832–41. doi:10.1016/j.bbalip.2017.05.005.
[28] Radojkovic C, Genoux A, Pons V, Combes G, De Jonge H, Champagne E, et al. Stimulation of Cell Surface F1-ATPase Activity by Apolipoprotein A-I Inhibits Endothelial Cell Apoptosis and Promotes Proliferation. Arter Thromb Vasc Biol 2009;29:1125–30. doi:10.1161/ATVBAHA.109.187997.
[29] Cavelier C, Ohnsorg PM, Rohrer L, von Eckardstein A. The beta-Chain of Cell Surface F0F1 ATPase Modulates ApoA-I and HDL Transcytosis Through Aortic Endothelial Cells. Arter Thromb Vasc Biol 2012;32:131–9. doi:ATVBAHA.111.238063 [pii] 10.1161/ATVBAHA.111.238063.
[30] Föger B, Ritsch A, Doblinger A, Wessels H, Patsch JR. Relationship of plasma cholesteryl ester transfer protein to HDL cholesterol: Studies in normotriglyceridemia and moderate hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1996;16:1430–6. doi:10.1161/01.ATV.16.12.1430.
[31] Hayek T, Azrolan N, Verdery RB, Walsh A, Chajek-Shaul T, Agellon LB, et al. Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism: Studies in transgenic mice. J Clin Invest 1993;92:1143–52. doi:10.1172/JCI116683.
[32] Feller S, Boeing H, Pischon T. Body mass index, waist circumference, and the risk of type 2 diabetes mellitus: implications for routine clinical practice. Dtsch Arztebl Int 2010;107:470–6. doi:10.3238/arztebl.2010.0470.
[33] Maeda N, Funahashi T, Matsuzawa Y, Shimomura I. Adiponectin, a unique adipocyte-derived factor beyond hormones. Atherosclerosis 2020;292:1–9. doi:10.1016/j.atherosclerosis.2019.10.021.
[34] Kwak SY, Chung IH, Kang J, Perakakis N, Yoo EH, Lee J, et al. Sex specific effect of ATPase inhibitory factor 1 on body weight: studies in high fat diet induced obese mice and genetic association studies in humans. Metabolism 2020;105:154171. doi:10.1016/j.metabol.2020.154171.
[35] Kahancová A, Sklenář F, Ježek P, Dlasková A. Overexpression of native IF1 downregulates glucose-stimulated insulin secretion by pancreatic INS-1E cells. Sci Rep 2020;10:1551. doi:10.1038/s41598-020-58411-x.
[36] Kahancová A, Sklenář F, Ježek P, Dlasková A. Regulation of glucose-stimulated insulin secretion by ATPase Inhibitory Factor 1 (IF1). FEBS Lett 2018;592:999–1009. doi:10.1002/1873-3468.12991.
[37] Zhang K, Bao R, Huang F, Yang K, Ding Y, Lauterboeck L, et al. ATP synthase inhibitory factor subunit 1 regulates islet β-cell function via repression of mitochondrial homeostasis. Lab Investig 2022;102:69–79. doi:10.1038/s41374-021-00670-x.
[38] Formentini L, Ryan AJ, Gálvez-Santisteban M, Carter L, Taub P, Lapek JD, et al. Mitochondrial H+-ATP synthase in human skeletal muscle: contribution to dyslipidaemia and insulin resistance. Diabetologia 2017;60:2052–65. doi:10.1007/s00125-017-4379-z.
[39] Conte M, Sabbatinelli J, Chiariello A, Martucci M, Santoro A, Monti D, et al. Disease-specific plasma levels of mitokines FGF21, GDF15, and Humanin in type II diabetes and Alzheimer’s disease in comparison with healthy aging. GeroScience 2021;43:985–1001. doi:10.1007/s11357-020-00287-w.
[40] Lehtonen JM, Auranen M, Darin N, Sofou K, Bindoff L, Hikmat O, et al. Diagnostic value of serum biomarkers FGF21 and GDF15 compared to muscle sample in mitochondrial disease. J Inherit Metab Dis 2021;44:469–80. doi:10.1002/jimd.12307.
[41] Tsygankova PG, Itkis YS, Krylova TD, Kurkina M V., Bychkov IO, Ilyushkina AA, et al. Plasma FGF‐21 and GDF‐15 are elevated in different inherited metabolic diseases and are not diagnostic for mitochondrial disorders. J Inherit Metab Dis 2019;42:918–33. doi:10.1002/jimd.12142.
[42] Boutari C, Pappas PD, Theodoridis TD, Vavilis D. Humanin and diabetes mellitus: A review of in vitro and in vivo studies. World J Diabetes 2022;13:213–23. doi:10.4239/wjd.v13.i3.213.
[43] Mizuno M, Kuno A, Yano T, Miki T, Oshima H, Sato T, et al. Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts. Physiol Rep 2018;6:e13741. doi:10.14814/phy2.13741.
[44] de Marañón AM, Canet F, Abad-Jiménez Z, Jover A, Morillas C, Rocha M, et al. Does Metformin Modulate Mitochondrial Dynamics and Function in Type 2 Diabetic Patients? Antioxid Redox Signal 2021;35:377–85. doi:10.1089/ars.2021.0019.
[45] Sawicki KT, Ben-Sahra I, McNally EM. Sglt2 inhibition on cardiac mitochondrial function: Searching for a sweet spot. J Am Heart Assoc 2021;10:e021949. doi:10.1161/JAHA.121.021949.
[46] Esparza-Moltó PB, Nuevo-Taρioles C, Chamorro M, Nájera L, Torresano L, Santacatterina F, et al. Tissue‐specific expression and post‐transcriptional regulation of the ATPase inhibitory factor 1 (IF1) in human and mouse tissues. FASEB J 2019;33:1836–51. doi:10.1096/fj.201800756R.